Biogen chalks up another failure, but investors' eyes remain firmly on Alzheimer's

illustration of brain using branches for AI
Biogen appears to be an Alzheimer's-focused biotech again. (Pixabay)

Amid all the talk about aducanumab and whether it can be approved in Alzheimer’s disease next year in a classic phoenix from the flames tail, Biogen has served up another trial flop.

In a relatively brief release this morning, the Big Biotech said a midstage test of its experimental med gosuranemab in progressive supranuclear palsy (PSP) failed to hit statistical significance in its primary endpoint.

It also failed on secondary endpoints in the so-called Passport trial, which was trying to help patients with PSP, a degenerative disease involving the gradual deterioration and death of specific volumes of the brain.

Whitepaper Download

Reducing the Complexity and Costs of Channel Planning and Logistics

How can you make the process of bringing your product to market less complex while also reducing costs? This Whitepaper identifies opportunities to simplify channel strategies for biopharma companies, their customers and patients. Discover how you can deliver savings and innovation to your business.

Testing for the drug against this target will now “not be pursued” Biogen said, which licensed the drug from Bristol-Myers Squibb.

But it’s not the end of the line for the drug, as a phase 2 test, known as Tango, will continue. And guess what it’s targeting? That’s right, Alzheimer’s. It says this makes senses “given differences in disease pathology.”

The drug is a humanized monoclonal antibody that targets N-terminal tau, one of two main theories after amyloid on what can cause Alzheimer’s, and can also cause other central nervous system disorders, such as PSP.

“We are disappointed with the efficacy results of the Phase 2 Passport study,” said Alfred Sandrock Jr., M.D., Ph.D., the new executive vice president of R&D and chief medical officer at Biogen. “We remain unwavering in our commitment to advancing therapies that have the potential to address the significant unmet medical needs of people with neurodegenerative diseases who are faced with limited to no treatment options.”

This comes after Biogen saw a major failure for its other Alzheimer’s drug, aducanumab, earlier this year, although some data dredging and a seemingly more complimentary FDA means it will be trying for an approval next year, which some believe it could actually pull off.

Analysts at Jefferies said this latest flop was a “pipeline setback, but unlikely a surprise to the market” and follows other failures from drugs with similar mechanisms, like AbbVie’s attempt that flopped in the summer.

In a note to clients, the firm said: “Indeed, combined with what we knew from AbbVie earlier in July which is their phase 2 of a nearly-identical tau antibody that binds the N-terminus of tau also failed at an interim futility (stopped early due to no efficacy) makes it pretty clear the tau hypothesis is tricky as PSP is one of the most highly prevalent 'tauopathy' diseases due to significantly high over-expression of tau and the aggressive nature of the disease.”

Suggested Articles

The clinical testing giant LabCorp will now begin rolling out a blood test for lung cancer developed by Resolution Bioscience.

Silverback Therapeutics reeled in $85 million to advance its lead antibody-drug conjugate through the clinic and develop its earlier-stage pipeline.

Cognoa aims to equip pediatricians with an AI-powered app that can spot the signs of autism, allowing them to diagnose in the doctor's office.